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Aim To assess the measures of disease frequency and de-
termine the clinical features of primary biliary cholangitis 
(PBC) in two Croatian regions.
Methods Databases of two tertiary hospitals, one located 
in the continental and one in the coastal region of Croa-
tia, were retrospectively searched for PBC patients diag-
nosed from 2007 to 2018. Epidemiologic data analysis 
was restricted to patients from each hospital’s catchment 
area. We analyzed factors related to response to therapy 
and event-free survival (EFS), defined as absence of ascites, 
variceal bleeding, encephalopathy, hepatocellular carci-
noma, liver transplantation (LT), or death. In addition, we 
determined clinical and demographic data of transplanted 
PBC patients.
Results Out of 83 PBC patients, 86.7% were female, with 
a median age at diagnosis of 55 years. Average PBC inci-
dence for the 11-year period was 0.79 and 0.89 per 100 000 
population, whereas the point prevalence on December 
31, 2017 was 11.5 and 12.5 in the continental and coastal 
region, respectively. Of 76 patients with complete medical 
records, 21% had an advanced disease stage, 31.6% had 
an associated autoimmune condition, and all received ur-
sodeoxycholic acid. EFS rate at 5 years was 95.8%. In an age 
and sex-adjusted multivariate Cox regression model, the 
only factor significantly associated with inferior EFS was no 
response to therapy (HR = 18.4; P = 0.018). Of all Croatian 
patients who underwent LT, 3.8% had PBC, with the sur-
vival rate at 5 years after LT of 93.4%.
Conclusion This study gives pioneer insights into the epi-
demiological and clinical data on PBC in Croatia, thus com-
plementing the PBC map of Southeast Europe.
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Primary biliary cholangitis (PBC) is a chronic cholestatic liver 
disease, an autoimmune disease activated by still unknown 
environmental factors in genetically susceptible individu-
als (1-3). The disease primarily affects cholangiocytes, lead-
ing to ductal destruction and loss. Its diagnostic hallmark 
are antimitochondrial antibodies (AMA), which are direct-
ed against the E2 subunit of the pyruvate dehydrogenase 
complex in combination with chronic cholestasis, whereas 
liver biopsy is reserved only for serologically negative pa-
tients and patients suspected of having an overlap with 
other diseases, such as autoimmune hepatitis or scleros-
ing cholangitis (PSC) (4,5). Common clinical presentations 
include fatigue, right upper abdominal pain, and pruritus, 
accompanied by a range of different other autoimmune 
phenomena, while 50% of patients are asymptomatic (5-7). 
The worldwide incidence and prevalence rates per 100 000 
population range from 0.33 to 5.8 and from 1.91 to 40.2, 
respectively (8). The highest prevalence was reported in 
North America and Northern Europe, namely Great Britain 
and the Scandinavian countries (9), suggesting a west-east 
and north-south declining gradient (8). Most of the data 
about European population come from studies in Western 
European countries, while there are no population-based 
epidemiological studies in Central and South-East Europe. 
In Croatia, no data on PBC incidence and prevalence rates 
have been published. This makes it urgent to fill the knowl-
edge gap about the disease frequency and identify and 
more precisely quantify the risk factors and potential envi-
ronmental triggers. The aims of this study were 1) to gain 
preliminary insights into PBC incidence and prevalence, 
based on hospital database analysis from two centers lo-
cated in different geographic regions of Croatia; 2) to de-
termine the clinical features and outcomes of PBC patients 
from these two centers, and 3) to determine the clinical 
features and outcomes of PBC patients who underwent 
liver transplantation (LT).
PATIENTS AND METHODS
Study design and patient population
This retrospective hospital-based study was conducted 
from 2007 till 2017 at two tertiary hospitals: University Hos-
pital Dubrava, Zagreb (UHD), located in northwestern Cro-
atia, and University Hospital Centre Rijeka (UHR), located in 
southwestern Croatia. According to the organization of the 
national health service and 2011 Census data, these hos-
pitals provide health care services to the catchment areas 
of 331 288 and 296 195 inhabitants, respectively. Each pa-
tient’s residence in the hospital’s catchment area was veri-
fied by checking the records in the hospital’s electronic da-
tabase. We also analyzed clinical characteristics, response 
to ursodeoxycholic acid (UDCA) treatment, survival, and 
the occurrence of liver related complications based on 
available follow-up data. Furthermore, we analyzed and 
descriptively presented clinical characteristics of the pa-
tients who underwent LT at the University Hospital Merkur 
(UHM), Zagreb, from 2008 to 2019. The UHM is the highest-
volume LT center in Croatia, performing 115-130 LTs per 
year. Patients from this center were not included into the 
epidemiological analyses since they originated from all 
over Croatia and were selected according to the severity of 
liver disease and the need for LT.
Case-finding method and diagnostic criteria
Three trained medical doctors searched electronic data-
bases of the UHD and UHR for the records on all patients 
diagnosed with PBC according to the current EASL guide-
lines (5) from January 1, 2007 till December 31, 2017, and 
the database of UHM for patients diagnosed from Janu-
ary 1, 2008 till December 31, 2018. Patients presenting with 
persistent cholestatic liver test abnormalities, including el-
evated alkaline phosphatase (ALP) and/or gamma-glu-
tamyltransferase (GGT) levels, with or without hyperbiliru-
binemia, were screened for the presence of AMA. Patients 
positive for AMA were diagnosed with PBC, while others 
required liver biopsy to confirm the diagnosis.
Study outcomes
PBC incidence was estimated for the population residing at 
the catchment area of UHD and UHR for the period 2007-
2018. Incidence was calculated as the number of new PBC 
cases within one year in the numerator and the size of the 
catchment population in the denominator. Point preva-
lence on December 31, 2017 was calculated as the num-
ber of people with PBC in the numerator and the size of 
the catchment population in the denominator. To assess 
the prevalence, we identified all PBC patients alive at this 
date residing in the catchment areas of each of the two 
centers (including those who were diagnosed before 2007: 
from 1996 at UHD and from 1998 at UHR). Both measures 
of disease frequency were expressed per 100 000 general 
population per year (10).
We also obtained data on the clinical features of PBC pa-
tients: age of disease onset, sex, liver function tests, AMA 
status, and the presence of other autoimmune diseas-
es. Patients were further categorized as having early 
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stage PBC, defined by histologic grade I-II or by normal bili-
rubin and albumin values at enrolment in patients without 
liver biopsy, or advanced-stage disease (11). Response to 
UDCA therapy was evaluated in the subsample of patients 
who had available laboratory data across a 12-month period 
according to Paris II criteria (11). Non-adherence to therapy 
was self-reported by patients at regular visits. When follow-
up data were available, we analyzed survival and the occur-
rence of liver-related complications. Event free survival (EFS) 
was determined considering a composite endpoint defined 
as the absence of either liver decompensation (ascites, va-
riceal bleeding, hepatic encephalopathy, and/or jaundice), 
hepatocellular carcinoma (HCC), death of any cause, and/
or LT, whichever occurred first. For PBC patients who under-
went transplantation, we assessed pre-transplant character-
istics and conducted LT outcome analysis. This study was 
approved by the Ethics Committees of University Hospital 
Dubrava (No 2019/0602-04), University Hospital Center Ri-
jeka (No 2170-29-02/1-19-2), and University Hospital Merkur 
(No 03/1-4280/2), and all procedures were in accordance 
with the Helsinki Declaration of 1975, as revised in 2008.
Statistical analysis
Normality of distribution was tested using the Shapiro-Wilk 
test. Normally distributed numerical variables are present-
ed as mean ± standard deviation (SD) and were compared 
between the groups with use of the t test. Non-normally 
distributed numerical variables are presented as median 
and interquartile range (IQR) and were compared between 
the groups with use of the Mann-Whitney U test. Categor-
ical variables are presented as ratio and percentage and 
were compared between the groups with use of the Fisher 
exact test or χ2 test, where appropriate. Multivariate assess-
ment of factors related to response to therapy was done 
with use of the logistic regression. Survival analyses were 
based on Kaplan-Meier method. Survival curves were com-
pared using the Cox-Mantel version of the log-rank test 
(12). Data were screened for significant associations with 
survival using a custom made MS Excel workbook (13). 
Multivariate assessment of factors related to the time to 
event of interest was done using the Cox regression. The 
level of significance was set at P < 0.05. Analyses were per-
formed with the MedCalc Statistical Software, version 18.5 
(MedCalc Software bvba, Ostend, Belgium).
RESULTS
In total, 123 PBC patients were identified: 47 at UHD, 36 
at UHR, and 40 at UHM. Of these, 74 patients resided 
in the catchment areas of UHD and UH and were eligible 
for the analysis of PBC prevalence, 76 patients with retriev-
able data sets at the time of diagnosis were eligible for the 
assessment of clinical characteristics, 62 patients with avail-
able follow-up data were eligible for the assessment of re-
sponse to UDCA treatment, and 40 transplanted patients 
were eligible for the assessment of pre-transplant charac-
teristics of PBC LT candidates and LT outcome analysis.
Epidemiological analysis
When the epidemiological analysis was restricted to the 
patients residing in the catchment area of UHD (N = 38) 
and UHR (N = 36) who were alive on December 31, 2017, 
the point prevalence was 11.5 and 12.5 per 100 000 popu-
lation, respectively. The annual incidence per 100 000 pop-
ulation for the period from 2007 to 2018 ranged from 0.3 
to 1.21 in the catchment area of UHD (average incidence 
0.79) and from 0.34 to 3.04 in the catchment area of UHR 
(average incidence 0.89) (Figure 1). If these rates were rep-
resentative of Croatian population, the estimated number 
of PBC patients on December 31, 2017 would be between 
492 and 535.
Clinical features of non-transplanted PBC patients
Out of 83 PBC patients from both centers, 72 (86.7%) 
were female, with the median age of 55 years at diag-
nosis (IQR 51-63; range 16-76). Seventy-six patients had 
all relevant clinical data available (Table 1). Among these 
76 patients, 11 (14.5%) had overlap syndromes with oth-
er autoimmune liver diseases: 9/76 (11.8%) with autoim-
mune hepatitis and 2/76 (2.6%) with PSC. Other autoim-
mune diseases were present in 24/76 (31.6%) patients, 
namely rheumatoid arthritis in 10/76 (13.2%), Hashimoto 
thyroiditis in 10/76 (13.2%), and systemic scleroderma in 
4/76 (5.3%) patients. Sicca syndrome, Sjogren syndrome, 
Graves’ disease, and celiac disease were present in one pa-
tient each.
All patients received UDCA treatment with a median dose 
of 1000 mg (IQR 750-1500). The data from 62 patients were 
evaluated after 12 months, and 54/62 (87.1%) patients 
achieved response (Table 1). Factors univariately associ-
ated with a higher odds ratio (OR) of not achieving the 
response were advanced disease stage (P = 0.008), higher 
histological stage (P = 0.019), and non-adherence to ther-
apy (P = 0.002). In an age- and sex-adjusted multivariate 
model, advanced stage of disease remained significantly 
associated with non-response to therapy with OR = 28.4 
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(P = 0.006). Histological stage was omitted from the analy-
sis due to incomplete data.
The median follow-up of our patients lasted 39 months. Dur-
ing the follow-up, one patient died due to a liver-unrelated 
cause and five patients experienced liver decompensation. 
Since only one death was recorded in the whole group of 
patients, no further multivariate analyses regarding overall 
survival were performed. EFS rate at 5 years was 95.8%, and 
median EFS time was not reached (Figure 2). Factors uni-
variately associated with shorter EFS were age at diagno-
sis >59 years (hazard ratio [HR] = 4.7; P = 0.038), osteoporo-
sis (HR = 4.8; P = 0.043), advanced disease stage (HR = 16.9; 
P = 0.001), ALP≤110 (HR = 8; P = 0.031), total cholesterol ≤4.7 
(HR = 7.7; P = 0.011), triacylglycerols (TAG)≤1.22 (HR = 11.8; 
P = 0.038), platelets ≤188 (HR = 13.4; P = 0.002), albumin <39 
(HR = 9; P = 0.005), corticosteroid therapy (HR 5.8; P = 0.038), 
non-adherence to therapy (HR = 9.4; P = 0.017), and no re-
sponse to therapy at 12 months (HR = 12; P = 0.001). These 
parameters were analyzed in a series of age- and sex-ad-
justed multivariate Cox regression models. The factors that 
remained significant after adjustments were total choles-
terol ≤4.7 (HR = 14.4; P = 0.047), platelets ≤188 (HR = 48.2; 
P = 0.022), albumin <39 (HR = 39.8; P = 0.032), and no re-
sponse to therapy (HR = 16.8; P = 0.024). When we analyzed 
these factors together in an age- and sex-adjusted multi-
variate Cox regression model, the only factor significantly 
associated with inferior EFS remained no response to ther-
apy (HR = 18.4; P = 0.018).
Clinical features of LT candidates with PBC
Among 1051 patients who underwent LT at the UHM in 
the period 2008–2019, 40 (3.8%) were transplanted due to 
PBC. Of them, 97.5% were women, and median age at LT 
was 59 years (IQR 53-63). In all patients, the primary indica-
FIGURE 1. The number of incident cases of primary biliary cholangitis (PBC) per 100 000 population per year diagnosed at two Croa-
tian tertiary hospitals from 2007 to 2018. Checkered – University Hospital Dubrava (UHD); gray – University Hospital Rijeka (UHR).
FIGURE 2. Event free survival (EFS) curve of primary biliary 
cholangitis (PBC) patients
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tion for LT was liver cirrhosis with complications, while 2/40 
(5%) also had HCC, 2/40 (5%) had overlap with PSC, and 
1/40 (2.5%) had intractable pruritus.
Median model of end-stage liver disease score was 17 (IQR 
14-21). Overall survival at 5 years was 93.4%. Two (2/40, 5%) 
patients died due to cardiovascular complications more 
than 1 year after LT. Four patients (4/40, 10%) experienced 
biopsy-proven disease relapse at a median of 4.5 years 
(IQR 4-5). All relapses at diagnosis occurred in early disease 
stages, except in one patient, with a relapse 9 years after LT, 
who was in advanced stage of fibrosis. Following the con-
TABLE 1. Patients characteristics for the whole cohort and stratified by response to ursodeoxycholic acid (UDCA)
Characteristics
Whole cohort 
(n = 76)
No response to treatment 
(n = 8)
Response to treatment 
(n = 54) P
Age (years), median (IQR)   56 (51-63)   56 (51-62)   63 (53-67) 0.141
Male sex, n (%)    9/76 (11.8)    0/8 (0)    8/54 (14.8) 0.581
AMA positive, n (%)   56/76 (73.7)    7/8 (87.5)   39/54 (72.2) 0.668
AMA M2 positive, n (%)   31/58 (53.4)    4/5 (80)   26/48 (54.2) 0.374
ANA positive, n (%)   25/65 (38.5)    4/7 (57.1)   19/49 (38.8) 0.429
IgM (g/L), median (IQR)    3.1 (1.9-4.5)    4.4 (4.4-5.1)    3 (2-4.5) 0.089
Nausea, n (%)   23/76 (30.3)    3/8 (37.5)   12/54 (22.2) 0.388
Fatigue, n (%)   27/76 (35.5)    1/8 (12.5)   20/54 (37) 0.247
Pruritus, n (%)   18/76 (23.7)    3/8 (37.5)   13/54 (24.1) 0.414
Osteoporosis, n (%)   16/76 (21.1)    2/8 (25)   12/54 (22.2) 1.000
Comorbid autoimmune diseases, n (%)   24/76 (31.6)    3/8 (37.5)   17/54 (31.5) 0.705
Advanced stage, n (%)   13/62 (21)    5/8 (62.5)    8/54 (14.8) 0.008
Histological stage, n (%)
 0    1/33 (3)    0/2 (0)    1/31 (3.2)
0.019
 1    9/33 (27.3)    0/2 (0)    9/31 (29)
 2   15/33 (45.5)    0/2 (0)   15/31 (48.4)
 3    4/33 (12.1)    1/2 (50)    3/31 (9.7)
 4    3/33 (9.1)    1/2 (50)    2/31 (6.5)
Overlap syndrome, n (%)   11/76 (14.5)    1/8 (12.5)   10/54 (18.5) 1.000
Initial UDCA dose (mg), median (IQR) 1000 (750-1500) 1000 (1000-1000) 1000 (750-1500) 0.697
Dose reduction, n (%)    8/60 (13.3)    0/6 (0)    8/54 (14.8) 0.585
Corticosteroids, n (%)   15/62 (24.2)    3/8 (37.5)   12/54 (22.2) 0.388
Other immunosuppressive drug, n (%)    5/62 (8.1)  1/8 (12.5)    4/54 (7.4) 0.511
Baseline bilirubin (μmol/L), median (IQR)   11 (8.2-18)   11.3 (7.6-21.5)   11 (8.2-16) 0.764
Baseline ALT (U/L), median (IQR)   43.5 (34-77.5)   46 (23-57.5)   43.5 (34-79.8) 0.266
Baseline AST (U/L), median (IQR)   42.5 (31-65.5)   35 (22-76.3)   43 (32-61) 0.389
Baseline ALP (U/L), median (IQR)  189 (160-248)  283.5 (98.3-414.8)  188 (163-245) 0.593
Baseline GGT (U/L), median (IQR)  123.5 (87.3-344.8)   91 (34-214.5)  126 (91.5-344.8) 0.193
Baseline cholesterol (mmol/L), mean (SD)    5.9 ± 1.4    5.9 ± 0.8    5.9 ± 1.4 0.974
Baseline triacylglycerols (mmol/L), median (IQR)    1.3 (1.1-1.5)    1.1 (1-1.3)    1.3 (1.1-1.5) 0.385
Baseline platelets ×109/L, mean (SD)  254.5 ± 74.9  261.5 ± 64.9  253.4 ± 76.8 0.778
Baseline albumin (g/L), mean (SD)   41.2 ± 3.7   40.7 ± 3.1   41.3 ± 3.8 0.695
Bilirubin at 12 months (μmol/L), median (IQR)   11 (8-12.9)    9 (8.3-16.5)   11 (8-12.8) 0.841
ALT at 12 months (U/L), median (IQR)   30 (23.8-39)   32 (24-50)   30 (24-39) 0.738
AST at 12 months (U/L), median (IQR)   28 (23-39)   44 (26-55.5)   27 (23-34.8) 0.225
ALP at 12 months (U/L), median (IQR)  125 (89.8-151.3)  312 (155.5-346.5)  122 (90-142) 0.065
Platelets at 12 months ×109/L, mean (SD)  217.3 ± 84.4  178.3 ± 94.5  221.9 ± 82.9 0.235
Albumin at 12 months (g/L), median (IQR)   42 (39-43)   40 (36.3-43.8)   42 (39.5-43) 0.824
Non-adherence to UDCA therapy, n (%)    3/61 (4.9)    3/8 (37.5)    0/53 (0) 0.002
*IQR – interquartile range; SD – standard deviation; AMA – antimitochondrial antibodies; ANA – antinuclear antibodies; ALT – alanine transaminase; 
AST – aspartate transaminase ; ALP – alkaline phosphatase; IgM – immunoglobulin M; GGT – gamma glutamyltransferase.
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firmed relapse of PBC, all patients were treated with UDCA. 
None of the patients died or were re-transplanted due to 
a relapse of PBC.
DISCUSSION
In our study, the incidence of PBC per 100 000 population 
per year ranged between 0.3 and 1.21 in UHD and between 
0.34 and 3.04 in UHR catchment area. For the respective 
geographical regions, the point prevalence on December 
31, 2017 was 11.5 and 12.5 per 100 000 population.
Primary biliary cholangitis fits well to the definition of 
a rare disease (14). Epidemiological data are scarce and 
mainly collected in the western countries, with a few ex-
emptions from the Eastern hemisphere (8). To put our data 
into the regional context, PBC incidence and prevalence in 
the Czech Republic were 3.0 and 11.5 per 100 000 inhabit-
ants, respectively, and in Slovakia 1.45 and 14.5 per 100 000 
inhabitants, (courtesy of Prof. Lubomir Skladany, Banska 
Bystrica, Slovakia, personal communication). In the Italian 
population in Lombardy, the incidence was 1.67/100 000 
and the prevalence was 16 per 100 000 (15). These results 
support the existence of a declining northwest and south-
east epidemiological gradient within the European region. 
Still, the Greek island of Crete should be considered as an 
outlier, with the incidence of 2.1 per 100 000 and preva-
lence of 36.5 per 100 000 (16). The disparities in geographi-
cal distribution could be explained by different genetic 
background and environmental factors (8,16).
The temporal incidence trends observed in our study 
should be interpreted with caution since our sample size 
is rather small. However, despite limitations, the suspect-
ed rising incidence is in line with the global trends. The 
worldwide increase in the PBC prevalence could be facili-
tated by incidence rates in female population (8,17). The 
trends observed in our study can be explained by the im-
provements in diagnostic tools, increased disease aware-
ness, easier access to patients’ data as a result of digitalized 
patient registration, and potentially improved survival 
upon UDCA treatment (although the data on the latter 
are equivocal) (18-23).
As much as 86.7% patients in our study were middle-aged 
women and 73.7% were AMA positive. Symptoms were 
present in 50% of patients, most prevalently fatigue, nau-
sea, pruritus, and osteoporosis. Liver overlap syndrome 
coexisted in 14.5% and other autoimmune diseases in 
31.6% of patients, respectively. The clinical characteristics 
of our PBC patients were similar to those described previ-
ously (2).
We also assessed patients’ EFS and response to UDCA ther-
apy, as well as the factors related to both. Since only one 
patient in the entire cohort died, survival could not be fur-
ther analyzed. However, EFS was excellent, reaching 95.8% 
at 5 years of follow-up, most probably because the major-
ity of patients had earlier clinical stages of PBC at diagno-
sis. In these patients, UDCA therapy is expected to be more 
effective, leading to better survival. Indeed, the only factor 
that remained independently associated with a better out-
come, after adjustments for other factors in the multivari-
ate Cox regression analysis, was response to UDCA therapy. 
On the other hand, the factor that was independently asso-
ciated with a good response to UDCA therapy (according 
to Paris II criteria) was early-stage liver disease. Early clinical 
stage of PBC and adherence to UDCA therapy in the major-
ity of patients also explain such favorable EFS in our study. 
UDCA at a daily dose of 13-15 mg/kg represents the main-
stay of therapy, with a 50%-75% success rate (5). Therapy 
improves serum liver tests and slows down the rate of his-
tologic progression, without having consistent effects on 
the symptoms (24-26). This is mostly true for patients in the 
early stage of PBC, although other studies reported contro-
versial data (26,27). Several risk factors for disease progres-
sion and poor response to therapy were identified: female 
sex, younger age, symptom presence, baseline albumin 
and bilirubin values, liver stiffness values measured by tran-
sient elastography >9.6 kPa, and advanced histologic stage 
(28-32). For patients with poor response to therapy, obet-
icholic acid has been recently licensed a second-line op-
tion, acting as a powerful farnesoid receptor agonist with 
promising results (33).
In the transplanted cohort, 97.5% patients were female, 
pointing to a possible negative impact of female sex on 
the disease course. All patients were transplanted due to 
complications of liver cirrhosis. Interestingly, the median 
age at LT was only four years higher than the age in the 
non-transplanted group. This observation might be ex-
plained by the fact that transplanted patients have un-
identified factors responsible for a faster development of 
cirrhosis coupled with unresponsiveness to UDCA treat-
ment at advanced disease stages. However, we could not 
determine the exact effect of no response to UDCA and 
the exact disease stage at diagnosis due to the retrospec-
tive nature of study and the referral of the patients to 
the LT center only at the terminal stage of liver disease. 
Even though graft survival in our patients was 100%, 
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biopsy-proven recurrent PBC at a median time of 4.5 years 
reached 10%. This was in accordance with published data, 
which show that the recurrence of autoimmune diseases, 
including PBC, at a median time of 5 years ranges between 
10% and 50%; the differences may be partly attributable to 
the use of protocol vs clinically indicated liver biopsies and 
different diagnostic criteria in LT centers (34,35). However, 
the recurrent disease progresses slowly and has a minimal 
impact on graft function and patient survival (36).
The presented results could be partly influenced by study 
limitations. This study was limited to the tertiary care hos-
pitals’ databases since other data sources, such as pathol-
ogy archives or public health registers, are not established 
for PBC patients. Studies of PBC epidemiology have used 
various sources for case-finding, but the search of medi-
cal record databases, despite its limitations, was the most 
common approach (8). Although the hospital catchment 
areas were precisely geographically defined, it was not pos-
sible to determine the exact number of patients within the 
study base. This can be partly attributable to the lack of 
symptoms or nonspecific symptoms among PBC patients. 
Some patients might not have been recognized and re-
ferred to specialist care in the hospital, possibly leading to 
underdiagnosis, as previously described (8). It is a common 
popular belief that patients with advanced liver disease are 
addicted to alcohol (and in some cases there is overlap in-
deed), further leading to underestimation, as previously re-
ported (8). Data obtained by a retrospective review of medi-
cal records may be incomplete or missing. It was difficult to 
retrieve the data for patients diagnosed before 2007, when 
the electronic database was established, and some impor-
tant data were missing, so we limited our study to the pe-
riod from 2007 till 2018. The reliance on diagnoses recorded 
in electronic medical records also makes it difficult to stan-
dardize the diagnostic criteria, which is why we manually 
reviewed all cases and excluded questionable diagnoses, 
ensuring standardization to the greatest extent possible. 
Also, some patients lacked histologic data as the diagnosis 
was established by an alternative approach, such as spe-
cific AMA antibody testing. However, we believe that these 
numbers could not be significantly higher since most of 
the patients would have been registered during the follow-
up at their regular visits. Additional limitations of our study 
are retrospective design, rarity of the disease (14), and low 
number of events during the follow-up period, affecting 
the statistical power of the presented findings.
In conclusion, this is a pioneer work on epidemiology 
of PBC in Croatia. Despite limitations, it gives new in-
sight into the occurrence patterns of PBC in Europe, but 
further research is needed to fill the gap in data availability 
and verify our findings.
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